U.S. Markets closed
  • S&P 500

    3,821.35
    -20.59 (-0.54%)
     
  • Dow 30

    31,802.44
    +306.14 (+0.97%)
     
  • Nasdaq

    12,609.16
    -310.99 (-2.41%)
     
  • Russell 2000

    2,202.98
    +10.77 (+0.49%)
     
  • Crude Oil

    64.68
    -0.37 (-0.57%)
     
  • Gold

    1,679.80
    +1.80 (+0.11%)
     
  • Silver

    25.18
    -0.09 (-0.35%)
     
  • EUR/USD

    1.1855
    -0.0069 (-0.5809%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • Vix

    25.47
    +0.81 (+3.28%)
     
  • GBP/USD

    1.3822
    -0.0006 (-0.0428%)
     
  • USD/JPY

    108.9200
    +0.5380 (+0.4964%)
     
  • BTC-USD

    50,947.24
    +92.13 (+0.18%)
     
  • CMC Crypto 200

    1,045.17
    +20.96 (+2.05%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent fight with Gilead

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Andrew Chung
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By Andrew Chung

Jan 19 (Reuters) - The U.S. Supreme Court on Tuesday rejected Merck & Co Inc's bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc for infringing a patent in a dispute over a blockbuster hepatitis C treatment.

The justices declined to take up Merck's appeal of a lower court's ruling that overturned the massive damages verdict after finding that Merck's patent was invalid. (Reporting by Andrew Chung in New York; Editing by Will Dunham)